Astellas PharmaALPMF +10.51%73 PEG Ratio is 0.87 as of Jun. 28, 2026, which is 24% below its 10-year median of 1.15. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.67 (Fairly Valued). The stock has 4 warning signs investors should review. Among 346 Drug Manufacturers companies, Astellas Pharma ranks better than 73.41% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Astellas Pharma's PEG Ratio or its related term are showing as below:
ALPMF'
s PEG Ratio Range Over the Past 10 Years
Min: 0.4 Med: 1.15 Max: 21.51
Current: 0.87
During the past 13 years, Astellas Pharma's highest PEG Ratio was 21.51. The lowest was 0.40. And the median was 1.15.
ALPMF's PEG Ratio is ranked better than 73.41% of 346
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs ALPMF: 0.87
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Astellas Pharma (OTCPK:ALPMF) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Astellas Pharma PEG Ratio Related Terms
Astellas Pharma PEG Ratio Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Astellas Pharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Astellas Pharma (ALPMF) has a PEG Ratio of 0.87 as of Jun. 28, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Astellas Pharma and its competitors. This is 24% below median its historical median of 1.15. Over the past decade, Astellas Pharma's PEG Ratio has ranged from 0.40 to 21.51. According to the industry distribution chart, Astellas Pharma ranks #92 out of 346 companies in the Drug Manufacturers industry, placing it in the top 26.6%.
Is Astellas Pharma's PEG Ratio too high?
Astellas Pharma's current PEG Ratio of 0.87 is 24% below median its 10-year median of 1.15. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 21.51. The Drug Manufacturers industry median PEG Ratio is 1.67. Astellas Pharma's value of 0.87 is 47.9% below this industry median. Based on the distribution chart, Astellas Pharma ranks #92 out of 346 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's PEG Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #92 out of 346 companies for PEG Ratio. This puts Astellas Pharma in the upper half of its industry. The industry median PEG Ratio is 1.67. Astellas Pharma's value of 0.87 is 47.9% below this benchmark. Historically, Astellas Pharma's own PEG Ratio has ranged from 0.40 to 21.51 over the past decade. While the company's 10-year median is 1.15 vs. the industry median of 1.67, Astellas Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.67, based on 346 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current PEG Ratio of 0.87 is 47.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current PEG Ratio is 0.87, which is 24% below median its own 10-year median of 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.67, compared to a current price of $14.20 — trading 3.2% below its estimated fair value. The current PEG Ratio is 0.87, which is 24% below median its 10-year median of 1.15 and 47.9% below the Drug Manufacturers industry median of 1.67. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current PEG Ratio is 0.87 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $14.20 is trading 3.2% below its estimated GF Value™ of $14.67.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
PEG Ratio: 0.87 (24% below median its 10-year median of 1.15)
GF Value™: $14.67 vs. price of $14.20 (3.2% below fair value)
Industry Position: 47.9% below the Drug Manufacturers median (#92 of 346)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
